AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32864392 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Time Warping (DTW)
Number of subjects: 2
Study 32864448 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed barbecue maneuver (HSB)
Number of subjects: 54
Study 32864448 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Lempert maneuver (ML)
Number of subjects: 54
Study 32864448 — intervention group
Group type: COMPARATOR
Intervention: Sham maneuver (SM)
Number of subjects: 54
Study 32864480 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 30
Study 32864480 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 32864604 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity screening using the American Academy of Pediatrics 2-question food insecurity screen
Number of subjects: 200
Study 32864604 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews regarding food insecurity
Number of subjects: 200
Study 32864604 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment status assessment
Number of subjects: 200
Study 32864604 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the WIC program
Number of subjects: 200
Study 32864604 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening of families at FQHC
Number of subjects: 200
Study 32864625 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib, a selective inhibitor of PI3Kα
Number of subjects: 0
Study 32865059 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Management of Type 1 Diabetes for Chinese Adults (SMOD-CA) scale
Number of subjects: 243
Study 32865097 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR) calculated using Cockcroft-Gault equation
Number of subjects: 14980
Study 32865097 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR) calculated using Modification of Diet in Renal Disease equation
Number of subjects: 14980
Study 32865097 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR) calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on creatinine
Number of subjects: 14980
Study 32865097 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR) calculated using CKD-EPI equation based on cystatin C
Number of subjects: 14980
Study 32865293 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetrombopag 2.5 mg/day
Number of subjects: 32
Study 32865293 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetrombopag 5 mg/day
Number of subjects: 32
Study 32865293 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetrombopag 7.5 mg/day
Number of subjects: 32
Study 32865454 — intervention group
Group type: EXPERIMENTAL
Intervention: Wixela Inhub Dry Powder Inhaler
Number of subjects: 0
Study 32865505 — intervention group
Group type: EXPERIMENTAL
Intervention: i-Matter mobile health texting tool
Number of subjects: 282
Study 32865809 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir plus standard of care (SOC)
Number of subjects: 237
Study 32865809 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard of care (SOC)
Number of subjects: 237
Study 32866032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonacog gamma (BAX 326, RIXUBIS)
Number of subjects: 0
Study 32866179 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-field optical coherence tomography (FF-OCT)
Number of subjects: 16
Study 32866202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet App for the Simplified Gestational Age Score (T-SGAS)
Number of subjects: 8591
Study 32866219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model including 11 variables associated with hypotension
Number of subjects: 934
Study 32866219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model excluding unstable patients
Number of subjects: 934
Study 32866540 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for CKD progression
Number of subjects: 3379
Study 32866540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac markers, plasma CXCL12, urinary NGAL
Number of subjects: 3379
Study 32866988 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal allografts
Number of subjects: 8
Study 32867535 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache onset within 7 days of head injury
Number of subjects: 193
Study 32867535 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache onset between 8 days and 3 months after head injury
Number of subjects: 193
Study 32867535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing migraine before head injury
Number of subjects: 193
Study 32867535 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache onset based on sex, headache phenotype, or mechanism of injury
Number of subjects: 193
Study 32867535 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache phenotype comparison within 7 days
Number of subjects: 193
Study 32867535 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation regarding ICHD-3 diagnostic criteria
Number of subjects: 193
Study 32867573 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E treatment for 4 weeks
Number of subjects: 0
Study 32867573 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-HNE protein adducts detection
Number of subjects: 0
Study 32867573 — intervention group
Group type: EXPERIMENTAL
Intervention: Human needle-biopsy liver samples
Number of subjects: 0
Study 32867679 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of mid-arm circumference (MAC)
Number of subjects: 300
Study 32867679 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight measurement
Number of subjects: 300
Study 32867679 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI measurement
Number of subjects: 300
Study 32867679 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard finger cuffs
Number of subjects: 300
Study 32867679 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese parturients
Number of subjects: 300
Study 32867698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Sabin IPV
Number of subjects: 0
Study 32867698 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose Sabin IPV
Number of subjects: 0
Study 32867698 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Sabin IPV
Number of subjects: 0
Study 32867698 — intervention group
Group type: COMPARATOR
Intervention: Control Sabin IPV
Number of subjects: 0
Study 32867698 — intervention group
Group type: COMPARATOR
Intervention: Control Salk IPV
Number of subjects: 0
Study 32867698 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antibody titer < 1:8
Number of subjects: 0
Study 32867698 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antibody titer 1:8 ~ < 1:32
Number of subjects: 0
Study 32867698 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antibody titer ≥ 1:32
Number of subjects: 0
Study 32867715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab in combination with FOLFOXIRI/bevacizumab every 2 weeks for 8 cycles followed by maintenance with bevacizumab plus nivolumab every 2 weeks.
Number of subjects: 70
Study 32867715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab in combination with FOLFOXIRI/bevacizumab
Number of subjects: 70
Study 32867719 — intervention group
Group type: EXPERIMENTAL
Intervention: Group penalized generalized estimating equation (PGEE) method for ERP data analysis
Number of subjects: 0
Study 32867720 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD patients (17)
Number of subjects: 51
Study 32867720 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ADPKD patients (16)
Number of subjects: 51
Study 32867720 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (18)
Number of subjects: 51
Study 32867853 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' clinical evaluation including DMFT and caries free rates.
Number of subjects: 702
Study 32867853 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DMFT score associated with personal variables.
Number of subjects: 702
Study 32867853 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower caries free rates associated with personal variables.
Number of subjects: 702
Study 32867853 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression for total DMFT.
Number of subjects: 702
Study 32867853 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression for caries free.
Number of subjects: 702
Study 32868037 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone 30 mg IV infusion over 60 min
Number of subjects: 30
Study 32868326 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Number of subjects: 0
Study 32868346 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flucloxacillin 500 mg-1 g four times a day
Number of subjects: 159
Study 32868349 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin as first-line glucose-lowering therapy
Number of subjects: 15992
Study 32868349 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin monotherapy at second line
Number of subjects: 15992
Study 32868349 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (≥75 years) and history of chronic kidney disease
Number of subjects: 15992
Study 32868349 — intervention group
Group type: COMPARATOR
Intervention: Patients from Africa
Number of subjects: 15992
Study 32868537 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 67
Study 32868537 — intervention group
Group type: COMPARATOR
Intervention: Control Episodic Thinking (CET)
Number of subjects: 67
Study 32869689 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient portal use for telerehabilitation
Number of subjects: 0
Study 32869840 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty liver disease (FLD)
Number of subjects: 114
Study 32869840 — intervention group
Group type: COMPARATOR
Intervention: Non-black race
Number of subjects: 114
Study 32869840 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT levels
Number of subjects: 114
Study 32869840 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic risks (hypertension, hyperlipidemia, diabetes family history)
Number of subjects: 114
Study 32869924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (LDV/SOF)
Number of subjects: 0
Study 32870132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic susceptibility contrast MRI
Number of subjects: 94
Study 32870132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI
Number of subjects: 94
Study 32870132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravoxel incoherent motion MRI
Number of subjects: 94
Study 32870139 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest CT
Number of subjects: 0
Study 32870139 — intervention group
Group type: COMPARATOR
Intervention: RT-PCR
Number of subjects: 0
Study 32870250 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavorixafor 400 mg once daily
Number of subjects: 8
Study 32870265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 1124
Study 32870266 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare sequence variants (RSVs) in IHH-associated genes
Number of subjects: 106
Study 32870266 — intervention group
Group type: COMPARATOR
Intervention: Control women
Number of subjects: 106
Study 32870269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 92
Study 32871021 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture or acupressure plus analgesia
Number of subjects: 3076
Study 32871021 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy plus analgesia
Number of subjects: 3076
Study 32871021 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic therapy
Number of subjects: 3076
Study 32871021 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (foot and hand) plus analgesia
Number of subjects: 3076
Study 32871021 — intervention group
Group type: EXPERIMENTAL
Intervention: Music plus analgesia
Number of subjects: 3076
Study 32871506 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental supply of sips
Number of subjects: 1910
Study 32871506 — intervention group
Group type: EXPERIMENTAL
Intervention: Supply of sips from other sources
Number of subjects: 1910
Study 32871506 — intervention group
Group type: EXPERIMENTAL
Intervention: Supply of whole drinks by parents or others
Number of subjects: 1910
Study 32871506 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger quantities of alcohol supply
Number of subjects: 1910
Study 32871584 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 blockade
Number of subjects: 5
Study 32871584 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1/PD-L2 copy gain or amplification
Number of subjects: 5
Study 32871584 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial analysis of tumor microenvironment
Number of subjects: 5
Study 32871584 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbiased clustering of spatially resolved immune signatures
Number of subjects: 5
Study 32871668 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported anxiety
Number of subjects: 107
Study 32871668 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 107
Study 32871668 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscientiousness (personality dimension)
Number of subjects: 107
Study 32871668 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 107
Study 32871668 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR)
Number of subjects: 107
Study 32873058 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic awareness (PA)
Number of subjects: 377
Study 32873058 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a predictor of PA
Number of subjects: 377
Study 32873058 — intervention group
Group type: EXPERIMENTAL
Intervention: Goals of care discussions (GOCD)
Number of subjects: 377
Study 32873121 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated analyses using artificial intelligence-based software for biventricular parameters including ejection fraction (EF)
Number of subjects: 1017
Study 32873121 — intervention group
Group type: COMPARATOR
Intervention: Manual assessments of biventricular parameters including ejection fraction (EF)
Number of subjects: 1017
Study 32873131 — intervention group
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux DCB followed by Pulsar-18 bare metal stent
Number of subjects: 120
Study 32873157 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicontext (MC) approach
Number of subjects: 8
Study 32873195 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of the '5-2-1' screening criteria
Number of subjects: 0
Study 32873237 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 113
Study 32873237 — intervention group
Group type: COMPARATOR
Intervention: Thoracic computed tomography (CT)
Number of subjects: 113
Study 32873270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense TPF (ddTPF) chemotherapy with cisplatin and docetaxel 50 mg/m2 on day 1, leucovorin 250 mg/m2 on day 1, followed by 48-h continuous infusion of 2500 mg/m2 of 5-fluorouracil on day 1 and 2, every 2 weeks for 6 cycles followed by radiotherapy.
Number of subjects: 58
Study 32873343 — intervention group
Group type: EXPERIMENTAL
Intervention: Chidamide, decitabine, cytarabine, aclarubicin, and G-CSF (CDCAG)
Number of subjects: 93
Study 32873586 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCD, DiaRem, Ad-DiaRem, DiaBetter, and individualized metabolic surgery scores
Number of subjects: 363
Study 32873586 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes duration alone
Number of subjects: 363
Study 32873668 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I interferon gene signature (IFNGS) status measured by a four-gene test, with scores compared to a pre-established cut-off.
Number of subjects: 900
Study 32873915 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib combined with cyclosporine and methotrexate
Number of subjects: 0
Study 32873915 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32873924 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR-directed gene editing targeting the beta globin gene.
Number of subjects: 0
Study 32874062 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm symptoms
Number of subjects: 381
Study 32874062 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 381
Study 32874062 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroscopic screening based on alarm symptoms
Number of subjects: 381
Study 32874376 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) achieved by 4 cycles of 5-minute inflation of a cuff on the left upper arm to 200 mm Hg followed by 5-minute deflation.
Number of subjects: 101
Study 32874376 — intervention group
Group type: COMPARATOR
Intervention: Control group with a deflated cuff placed on the left arm for 40 minutes.
Number of subjects: 101
Study 32874573 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib (4.0 mg dose)
Number of subjects: 3
Study 32874593 — intervention group
Group type: EXPERIMENTAL
Intervention: Onymous Arm (descriptive norms messages with personal identification)
Number of subjects: 311
Study 32874593 — intervention group
Group type: COMPARATOR
Intervention: Anonymous Arm (descriptive norms messages without personal identification)
Number of subjects: 311
Study 32874593 — intervention group
Group type: EXPERIMENTAL
Intervention: Onymous Arm
Number of subjects: 311
Study 32874593 — intervention group
Group type: COMPARATOR
Intervention: Anonymous Arm
Number of subjects: 311
Study 32874839 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical atropine 0.125%
Number of subjects: 96
Study 32875141 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome intervention
Number of subjects: 0
Study 32875141 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient feeding with controlled metabolic phenotyping
Number of subjects: 0
Study 32875267 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary food supplementation
Number of subjects: 0
Study 32875289 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA treatment
Number of subjects: 730
Study 32875313 — intervention group
Group type: EXPERIMENTAL
Intervention: High GFR (GFR ≥ 52)
Number of subjects: 1782
Study 32875313 — intervention group
Group type: COMPARATOR
Intervention: Low GFR (GFR < 52)
Number of subjects: 1782
Study 32875390 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedural MTT (Mean Transit Time)
Number of subjects: 5
Study 32875390 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedural PBF (Perfusion Blood Flow)
Number of subjects: 5
Study 32875390 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedural PBV (Perfusion Blood Volume)
Number of subjects: 5
Study 32876113 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU survival at 28 days
Number of subjects: 300
Study 32876113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital survival at 60 days
Number of subjects: 300
Study 32876113 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of advanced life support
Number of subjects: 300
Study 32876349 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg IV every 4 weeks
Number of subjects: 2243
Study 32876903 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 231
Study 32876903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 32876998 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived substance use norms among jailed women
Number of subjects: 205
Study 32877212 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-Breath Washout
Number of subjects: 0
Study 32877212 — intervention group
Group type: COMPARATOR
Intervention: Spirometry
Number of subjects: 0
Study 32877220 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission hematocrit (HCT) in MOF group
Number of subjects: 57
Study 32877220 — intervention group
Group type: COMPARATOR
Intervention: Admission hematocrit (HCT) in non-MOF group
Number of subjects: 57
Study 32877254 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2; 4-µg and 10-µg) softgel vaginal insert
Number of subjects: 0
Study 32877349 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the official Singapore government's WhatsApp channel
Number of subjects: 1145
Study 32877349 — intervention group
Group type: COMPARATOR
Intervention: Increased exposure to COVID-19 news
Number of subjects: 1145
Study 32877349 — intervention group
Group type: COMPARATOR
Intervention: Increased time spent receiving COVID-19 updates
Number of subjects: 1145
Study 32877411 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to PAD monitoring (pain monitoring)
Number of subjects: 1323
Study 32877411 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to PAD monitoring
Number of subjects: 1323
Study 32877411 — intervention group
Group type: COMPARATOR
Intervention: Non-adherence to PAD monitoring
Number of subjects: 1323
Study 32877524 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-lilotomab satetraxetan
Number of subjects: 74
Study 32877573 — intervention group
Group type: EXPERIMENTAL
Intervention: UA-lowering drugs
Number of subjects: 211
Study 32877583 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib
Number of subjects: 364
Study 32877600 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 58
Study 32877600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 32877600 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (every 8 weeks)
Number of subjects: 58
Study 32877600 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (every 4 weeks)
Number of subjects: 58
Study 32878377 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months treatment (defocused communication and behavioural techniques)
Number of subjects: 24
Study 32878377 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 24
Study 32878566 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy (standard- and low-dose, ≥3× per week)
Number of subjects: 315